Progression of B-RAF Cancer Drug Discovery Collaboration
London, UK, 27 July 2006 - The Wellcome Trust Limited and The Institute of Cancer Research (The Institute) today announced a new alliance with GlaxoSmithKline to discover, develop and commercialize novel small molecule inhibitors of B-RAF, a key signal transduction enzyme, for use as anti-cancer agents. The new alliance builds on the partnership between the Wellcome Trust, The Institute, Cancer Research Technology Limited and Astex Therapeutics Limited entered into in February 2004.
Under the Agreement, The Wellcome Trust will be eligible for option exercise payments, and clinical development and regulatory milestone payments. In addition, The Wellcome Trust is eligible to receive royalties on commercial sales of approved products. The milestone and royalty revenues will be shared with The Institute, Cancer Research Technology and Astex.
To view the original press release from The Wellcome Trust please click here
|
